- Home
- INKT vs IRD Comparison
INKT vs IRD Comparison
Compare INKT & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- IRD
- Stock Information
- Founded
- INKT 2017
- IRD 2018
- Country
- INKT United States
- IRD United States
- Employees
- INKT N/A
- IRD N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- IRD
- Sector
- INKT Health Care
- IRD
- Exchange
- INKT Nasdaq
- IRD NYSE
- Market Cap
- INKT 28.8M
- IRD 59.1M
- IPO Year
- INKT 2021
- IRD N/A
- Fundamental
- Price
- INKT $28.86
- IRD $1.10
- Analyst Decision
- INKT Hold
- IRD Strong Buy
- Analyst Count
- INKT 3
- IRD 3
- Target Price
- INKT $37.50
- IRD $6.33
- AVG Volume (30 Days)
- INKT 2.7M
- IRD 744.9K
- Earning Date
- INKT 08-12-2025
- IRD 08-15-2025
- Dividend Yield
- INKT N/A
- IRD N/A
- EPS Growth
- INKT N/A
- IRD N/A
- EPS
- INKT N/A
- IRD N/A
- Revenue
- INKT N/A
- IRD $13,651,000.00
- Revenue This Year
- INKT N/A
- IRD $51.41
- Revenue Next Year
- INKT N/A
- IRD $68.84
- P/E Ratio
- INKT N/A
- IRD N/A
- Revenue Growth
- INKT N/A
- IRD N/A
- 52 Week Low
- INKT $4.56
- IRD $0.65
- 52 Week High
- INKT $76.00
- IRD $2.18
- Technical
- Relative Strength Index (RSI)
- INKT 60.80
- IRD N/A
- Support Level
- INKT $6.80
- IRD N/A
- Resistance Level
- INKT $76.00
- IRD N/A
- Average True Range (ATR)
- INKT 5.95
- IRD 0.00
- MACD
- INKT 3.73
- IRD 0.00
- Stochastic Oscillator
- INKT 35.31
- IRD 0.00
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.